MediWound (NASDAQ:MDWD) Stock Price Breaks Below Two Hundred Day Moving Average – Here’s What Happened

Shares of MediWound Ltd. (NASDAQ:MDWD) crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $15.10 and traded as low as $13.33. MediWound shares last traded at $13.65, with a volume of 73,110 shares changing hands.

Analyst Ratings Changes

Several equities research analysts have commented on MDWD shares. Alliance Global Partners restated a “buy” rating on shares of MediWound in a research report on Wednesday, September 16th. TD Cowen reiterated a “buy” rating on shares of MediWound in a research note on Thursday. Weiss Ratings downgraded shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of MediWound in a research report on Thursday, May 28th. Finally, Wall Street Zen cut shares of MediWound from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, MediWound presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

MediWound Price Performance

The company has a market capitalization of $177.84 million, a price-to-earnings ratio of -7.69 and a beta of 0.14. The firm has a fifty day simple moving average of $13.68 and a 200 day simple moving average of $15.08.

MediWound (NASDAQ:MDWD) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.01). MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%.The business had revenue of $3.09 million for the quarter, compared to analyst estimates of $2.59 million. Research analysts predict that MediWound Ltd. will post -2.27 EPS for the current year.

Insider Activity

In other news, COO Shmuel Hess sold 3,958 shares of the business’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 9.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in MediWound stock. Clal Insurance Enterprises Holdings Ltd lifted its stake in MediWound Ltd. (NASDAQ:MDWD) by 22.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 71,000 shares of the biopharmaceutical company’s stock after purchasing an additional 13,196 shares during the quarter. Clal Insurance Enterprises Holdings Ltd owned about 0.55% of MediWound worth $1,311,000 at the end of the most recent reporting period. 46.83% of the stock is owned by institutional investors.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative enzymatic therapies for tissue injury and wound care. The company’s products are designed to remove damaged or nonviable tissue while helping preserve healthy tissue, supporting wound management and healing.

MediWound’s lead commercial product is NexoBrid, a topical bromelain-based therapy used for the enzymatic removal of eschar in adults with deep partial-thickness and full-thickness thermal burns.